3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
5
Breast Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
3
Ovarian Neoplasms
2
mCRPC
1
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Hepatoblastoma
1
Hemangiosarcoma
1
Extensive Stage Lung Small Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Adenocarcinoma
1
Interventions
Temozolomide
41
Magnetic Resonance Spectroscopy
19
Radiotherapy
18
Specimen Handling
14
Radiation
12
Bevacizumab
11
Lomustine
9
pembrolizumab
6
fludarabine
5
Surgical Procedures, Operative
5
atezolizumab
4
Nivolumab
4
Ipilimumab
4
Cyclophosphamide
4
Carboplatin
4
Biopsy
4
cemiplimab
3
azeliragon
3
Immunoglobulin G
3
Disulfides
3
Aminolevulinic Acid
3
veliparib
2
trametinib
2
rocakinogene sifuplasmid
2
poly ICLC
2
olaparib
2
lutetium Lu 177 dotatate
2
durvalumab
2
dabrafenib
2
contrast agent BR1
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Glioblastoma
×
talazoparib
×
90 days
×
Clear all
No trials found.